75 results about "Tourette syndrome" patented technology

The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

Orthotic devices are provided that reduce or eliminate the manifestation of certain involuntary movements. Through the configuration and / or composition of the devices of the present invention, persons with certain neurologic disorders and neuro-psych disorders such as Tourette Syndrome and Chronic Tic Disorder may experience a reduction in involuntary movements and urges.

Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.

The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

The invention discloses a medicament for treating epilepsy and tourette syndrome and a preparation method thereof. The preparation method comprises the following steps of: crushing scorpion, acetic tortoise plastron, stiff silkworm and artificial bezoar into fine powder, extracting volatile oil from two traditional Chinese medicines, namely grassleaf sweelflag rhizome and tangerine peel, by steam distillation, filtering the aqueous solution, and storing the aqueous solution in another container for later use; and decocting seven herbs, such as tall gastrodia tuber and the like, with decoction dregs of the grassleaf sweelflag rhizome and the tangerine peel with water for two times, filtering the decoction, standing the decoction, filtering the decoction, performing concentration on the filtrate under reduced pressure until the filtrate becomes a thick paste, adding the powder of the scorpion, the acetic tortoise plastron, the stiff silkworm and the artificial bezoar into the thick paste, uniformly mixing, pelletizing the mixture, drying and cooling the pelletized mixture, uniformly spraying the volatile oil onto the pelletized mixture, and filling the pelletized mixture into capsules to obtain the medicament. The medicament of the invention reduces the side effect of the Western medicine for treating epilepsy and has very good effect.

A preparation method of traditional Chinese medicinal oral liquid for treating tourette syndrome of children includes performing reflux extraction on radix paeoniae alba, bombyx batryticatus, gastrodia elata, uncaria rhynchophylla, radix curcumae, pheretima and buthus martensii, filtering, recovering ethanol, concentrating, adding distilled water, standing, and refrigerating; mixing rehmannia glutinosa libosch and the medicinal residue, decocting in water, filtering, concentrating, adding ethanol, standing, collecting supernatant, and filtering to obtain water extraction / ethanol precipitation liquid; mixing water extraction / ethanol precipitation liquid and ethanol extraction / water precipitation liquid, recovering ethanol, heating, concentrating, standing, filtering to obtain filtrate; mixing 1 / 3 volume of the filtrate with steviosin, stirring, mixing with the rest 2 / 3 of the filtrate, adding ethylparaben, adding water, regulating pH value, and standing; and centrifuging, collecting supernatant, adding water to regulate total volume to 1,000 mL, stirring, subpackaging, and sterilizing. Through improvement on the basis of the original process, the preparation method provided by the invention improves preparation appearance, solves the problems of poor clarity and stability in the original process, and ensures safety and efficacy of medicament in children.

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The disclosure relates to the genome-wide identification of “rearrangement hotspots”. The disclosure also relates to a microarray chip system for use in detecting genomic rearrangements and a method of manufacturing a microarray chip system useful for detecting genomic rearrangements. The disclosure also relates to methods for detecting genomic rearrangements associated with genetic diseases. The disclosure further relates to methods for using copy number variants in chromosome 2 for detecting Tourette Syndrome.

The invention discloses a Chinese medicament for treating multiple tourette syndrome, which consists of the following raw material medicaments in part by weight: 5 to 10 parts of cooked rehmannia, 20 to 35 parts of white paeony root, 10 to 15 parts of tall gastrodia tuber, 12 to 16 parts of grassleaf sweelflag rhizome, 2 to 8 parts of nacre, 2 to 8 parts of thinleaf milkwort root-bark, 2 to 8 parts of bupleurum, 2 to 8 parts of oyster, 2 to 8 parts of kudzuvine root, 2 to 8 parts of indigowoad root, 2 to 8 parts of heterophylly falsestarwort root, 2 to 8 parts of Indian buead, 12 to 18 parts of tangerine peel, 2 to 8 parts of pinellia tuber, 2 to 8 parts of golden thread, 2 to 8 parts of biond magnolia flower, 2 to 8 parts of siberian cocklour fruit, 2 to 8 parts of figwort root, 2 to 8 parts of Chinese gentian and 12 to 18 parts of Chinese eaglewood. The medicaments are matched to furthest exert synergistic effects, so that the Chinese medicament has better effects of calming liver wind, and sweeping phlegm and opening orifices, and controls involuntary tic and phonation.

The invention discloses a medicinal combination used for curing gilles de la tourettes syndromes, and a method for preparing the medicinal combination, which belongs to the field of a Chinese traditional medicine. The medicinal combination is prepared from uncaria, japanese sweetflag, oyster, magnet, scorpion, coptis, pawpaw, club moss, magnolia flower, chrysanthemum, and so on. Effective ingredients are extracted through wet distillation, decoction in water, or in ethanol and so on based on the different characteristics of the medicaments. Capsules, tablets, granules, powder, pills or oral are prepared in this way. The medicinal combination has the function of calming the endopathic wind and resolving phlegm, which shows specific and safe curative effects for gilles de la tourettes syndromes of children. The invention further discloses a method used for controlling the quality of the medicinal combination.

One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries.

The invention discloses a novel isoquinoline compound, and a synthetic method thereof as well as an application of the compound, which is used as an agonist or an inhibitor of dopamine receptors in the medicines for treating Parkinson's disease, schizophrenia, tristimania, Tourette syndrome, attention-deficit hyperkinetic syndrome, pituitary tumor, etc. The constitutional formula of the compound is as follows: wherein, R1 is the hydrocarbyl with a H, C1-C10 linear chain or fork chain, heteroatom-substituted hydrocarbyl and aromatic or fatty heterocycle or non-heterocycle substituted alkyl; X is carbonyl, methylene and imidogen, and is more than C-OH or more than C=; Y is carboxide, methylene and imidogen, and is more than C= or more than C=N-OH; the compound can have no D cycle or the D cycle can be various heterocycles of substituted five-membered fat and substituted six-membered fat or substituted five-membered aromatic and six-membered aromatic; n is 0-3.

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The invention discloses a traditional Chinese medicine preparation for treating heart and spleen heat type tourette syndrome. Doctors of all dynasties think that the tourette syndrome is mainly based on liver wind argument, relates to internal organs, particularly liver and is in close relation with heart, spleen and kidney. Therefore, traditional Chinese medicines such as twoleaf swertia herb, littlefruit heartseed fruit, Isodon amethystoides, herpetospermum pedunculosum, Siberian clematis stem, apocynum venetum, common leafflower herb with root, common pearleverlasting herb, longleaf bastardtoadflax herb and delavay honeysuckle herb with the effects of clearing away the heart-fire and relieving spleen heat and calming wind and stopping spasm are decocted into decoction. The clinical test in the institute proves that the total effective rate is 92.0 percent and is obviously superior to 68.0 in the control group, and the traditional Chinese medicine preparation has an obvious curative effect and is worthy of clinical popularization and application.

The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.

The invention relates to a compound risperidone subcutaneous embedded sustained-release preparation and a preparation method thereof. The sustained-release preparation is prepared from the following raw materials in parts by weight: 100 parts of risperidone and 0.00247 part of propionic acid sustained-release preparation. The preparation method comprises the following step of uniformly mixing risperidone and the propionic acid sustained-release preparation into granules which are wrapped in a plurality of medical silicon rubber tubes. The compound risperidone subcutaneous embedded sustained-release preparation provided by the invention can be guided and embedded in a loose part of the subcutaneous tissue of the inferior abdominal wall of a patient by means of a small incision with a sleeve needle after getting a satisfactory effect of acute treatment of the patient, and 8-10 subcutaneous embedded sustained-release preparations can be embedded at one time. The subcutaneous embedded sustained-release preparation is lasting in curative effect and economical and practical, and the one-time embedding curative effect is controlled within about 1 year. Medicines guided by the sustained-release preparation are slowly and uniformly released through a medical silica gel thin film wall to ensure stable and effective blood concentration so as to realize the purpose of maintaining treatment. The subcutaneous embedded sustained-release preparation provided by the invention is suitable for patients with various schizophrenia, mood disorders, multiple Tourette syndrome and other risperidone treatment indications.

Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and / or who have not been given organic nitrates.

The invention discloses a traditional Chinese medicine composition for treating childhood tourette syndrome and a preparation method thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is mainly composed of following raw material medicines, by weight: 9-15 parts of stir-fried atractylodes macrocephala koidz, 9-15 parts of white peony roots, 9-15 parts of bombyx batryticatus, 9-15 parts of periostracum cicada, 9-15 parts of flemingia philippinensis, 9-15 parts of dioscorea nipponica makino, 3-6 parts of zaocys dhumnade, 6-9 parts of eriocaulon buergerianum and 3-6 parts of radix glycyrrhizae. According to the traditional Chinese medicine theories, the formula of the compatibility of the medicine is formed according to a monarch-minister assistant-guide principle. The stir-fried atractylodes macrocephala koidz has effects of tonifying qi and fortifying spleen and drying dampness and inducing diuresis; the white peony roots have effects of nourishing blood and softening liver and calming liver and relieving spasm; the bombyx batryticatus has effects of dispelling wind and relieving spasm and resolving phlegm and dissipating binds; the periostracum cicada has effects of extinguishing wind and relieving spasm; the flemingia philippinensis has effects of dispelling wind and draining dampness and dispersing swelling and removing toxin; the dioscorea nipponica makino has effects of activating blood and freeing meridians; the zaocys dhumnade has effects of dispelling wind, freeing meridians and relieving spasm; the eriocaulon buergerianum has effects of clearing heat and calming liver and removing nebula to promote eyesight; and the radix glycyrrhizae has effects of tonifying spleen and boosting qi. The raw material medicines are combined and the traditional Chinese medicine composition has effects of fortifying spleen and calming liver, and extinguishing wind and relieving spasm.